Replies to post #13907 on GT Biopharma Inc (GTBP)

[SamuraiX]

OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)

OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.

OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year